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COMMENTARY
Sickle cell vaso-occlusive crisis: it’s a gut 
feeling
Seah H. Lim1*, Loren Fast1 and Alison Morris2
Abstract 
Insights in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease have changed significantly in 
the last decade. Various laboratory and clinical evidence have provided support to the pivotal role of activated neutro-
phils in this process. A recent study in murine sickle cell disease indicated that the intestinal microbiota is responsible 
for regulating the number of aged neutrophils, a subset of neutrophils that are overly activated. Reduction of these 
neutrophils in vivo protected the mice from fatal TNFα-induced vaso-occlusive crisis. In this paper, we discuss the rea-
sons why patients with sickle cell disease may have an abnormal intestinal microbiota and how this could contribute 
to the development of vaso-occlusive crisis. We also highlight the recent interest in studying the intestinal microbiota 
of patients with sickle cell disease and suggest that the next therapeutic approach for these patients may well be in 
the manipulation of the intestinal microbiota to restore the individual’s microbial landscape.
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The human intestine is colonized by thousands of differ-
ent microbial species. The gut microbiota plays a central 
role in microbial homeostasis, regulation of metabolism, 
and immune tolerance. A novel method involving the 
use of mass DNA sequencing targeting the 16S riboso-
mal RNA has allowed a comprehensive evaluation of the 
microbiome. This has led to clinical findings implicating 
dysbiosis in an assortment of systemic conditions [1–5].
Sickle cell disease (SCD) is a classic inherited disorder 
of a nucleotide mutation, causing a single amino acid 
substitution from glutamic acid to valine at position 6 on 
the β-globin subunit. This substitution leads to changes 
in the physical properties of the globin chain. During 
physiological stresses, e.g. infections, hypoxia, and dehy-
dration, hemoglobin S (HbS) polymerizes, causing eryth-
rocytes to adopt a sickle morphology and become more 
rigid, with the consequent expression of various cellu-
lar adhesion molecules, e.g. α4β1 [6] and Lu/BCAM [7] 
that may facilitate the physical interaction of the sickle 
erythrocytes with endothelium. However, the interac-
tion between sickle erythrocytes and the endothelium 
is unlikely to be the central issue in vaso-occlusive crisis 
(VOC) because there is a lack of correlation between the 
number of sickle erythrocytes observed in the peripheral 
blood and VOC symptoms or severity.
Neutrophils play a pivotal role in initiating VOC. Their 
importance has been highlighted in various laboratory 
studies and clinical observations [8–10]. In a mouse 
model of VOC, instead of attaching to endothelium, 
sickle erythrocytes more commonly adhered to activated 
neutrophils [8]. SCD patients have higher levels of solu-
ble CD62L, a serum marker of neutrophil activation [9]. 
Neutrophils from SCD patients also express higher levels 
of activation molecules, e.g. CD64 [9] and CD11b/CD18 
[10], that mediate their adherence to endothelium. These 
immobilized neutrophils may act as niduses for sickle 
erythrocytes to attach to [11] and cause VOC. Hemat-
opoietic growth factor administration to a SCD patient, 
who was a donor for hematopoietic progenitor cell trans-
plant, upregulated the activation molecules and led to 
fatal consequence [12]. Other observations that support 
a link of VOC with neutrophils include the correlation 
between higher neutrophil counts and severity of the dis-
ease [13], and between responses to hydroxyurea, irre-
spective of the hemoglobin F (HbF) levels, and decreased 
neutrophil counts [14]. Inflammatory cytokines [15–
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therefore, occurs as a result of the interplay between 
sickle erythrocytes, activated neutrophils, inflammatory 
cytokines, and endothelium, with activated neutrophils 
being the central players.
So what is the main source of stimulus responsible for 
inducing neutrophil activation in SCD patients? A novel 
theory that the intestinal microbiome is critical in trig-
gering VOC has recently been proposed [21]. Rapidly 
evolving understanding of the importance of the gut 
microbiome implicates changes in the composition and 
function of gut microbial communities in not only gas-
trointestinal diseases, but also in an assortment of sys-
temic conditions [1–5]. SCD may be the latest to join this 
list based on experimental evidence in animal models as 
well as clinical characteristics of SCD and VOC that sup-
port a theoretical framework of microbial involvement.
Limited data currently exist in animal models. A study 
in SCD mice demonstrated that the intestinal microbi-
ota was responsible for regulating the number of VOC-
promoting neutrophils [21]. Depletion of the intestinal 
microbiota with prolonged courses of combination anti-
biotics was associated with a corresponding reduction 
in the number of circulating aged neutrophils, a subset 
of neutrophils that are overly activated, and an improve-
ment in the clinical outcome from TNFα-induced VOC. 
This function of the intestinal microbiota in regulating 
aged neutrophils appeared to operate through Toll-like 
receptor (TLR)-mediated and myeloid differentiation 
factor 88 (Myd88)-mediated signaling mechanisms [21]. 
This work, therefore, highlights the importance of the 
intestinal microbiota in regulating ageing of neutrophils 
in SCD and that microbiota depletion reduces severity of 
experimental VOC.
Additional support for involvement of the microbiota in 
SCD stems from the observation that SCD patients have 
higher numbers of baseline activated neutrophils [9, 10] 
compared to healthy controls, and SCD patients receiv-
ing penicillin for prophylaxis have fewer circulating acti-
vated neutrophils [21]. As suggested by the mouse study 
[21], if intestinal microbes are the main source of activa-
tors of circulating neutrophils in SCD patients, it follows 
that there must be abnormalities in either the integrity of 
the intestinal barriers in SCD or a chronic disequilibrium 
of the intestinal microbiota, or both. The intestinal bar-
rier separates the intestinal lumen from the inner host. It 
consists of mechanical elements (mucus, epithelial layer), 
humoral elements (defensins, IgA), immunologic ele-
ments (lymphocytes, innate immune cells), muscular and 
neurological elements. Failure of the protective intesti-
nal barrier results in recurrent translocation of intestinal 
bacteria that can stimulate inflammation without caus-
ing overt infection or that can lead to bacteremia/sep-
ticemia. We hypothesize that both the intestinal barrier 
and the ability of the mucosa to support a normal intes-
tinal microbiota in SCD patient are compromised, due to 
segmental or global subclinical intestinal ischemia that 
occurs as a result of VOC in the splanchnic vasculature. 
The compromised intestinal barrier renders SCD patients 
more susceptible to recurrent translocation by bacterial 
inoculums not high enough to cause overt infections, but 
sufficient to activate neutrophils. Furthermore, as a result 
of the mucosa’s inability to support a normal microbiota, 
the normal intestinal microbiome is disturbed. In some 
patients, this disturbance may be worsened by certain 
diet, medications, or lifestyle that results in the produc-
tion of metabolites that stimulate neutrophil activation. 
Both bacterial translocation and intestinal dysbiosis likely 
contribute to the higher levels of circulating activated 
neutrophils observed in SCD patients.
The need for further research into the role of micro-
biota in mediating diseases was highlighted in May 2016 
when the White House announced the establishment of 
the National Microbiome Initiative. The Minority Coali-
tion for Precision Medicine (MCPM), which has an inter-
est in the interplay between intestinal microbiota and 
VOC, is involved in this initiative and aims to collect the 
stool samples from 500 donors with SCD and sickle trait. 
To confirm the hypothesis that the microbiota is critical 
in VOC, this study and others are needed to determine 
if an abnormal intestinal microbiome correlates with 
increased numbers of circulating activated neutrophils 
and more frequent VOC. Studies will also be needed to 
confirm the importance of specific bacteria or their func-
tion in SCD and VOC, and additional mechanistic animal 
studies will be needed to confirm associations seen in 
humans. Confirmation of the microbiome hypothesis of 
SCD will open up new avenues of therapeutic approach 
to establish and maintain a normal intestinal microbiota 
for patients with SCD such as use of pre- and pro-biotics, 
manipulation of intestinal microbial species using fecal 
microbiota transplant, and therapies to reduce bacterial 
burden and translocation.
In conclusion, VOC may now join the ever-expanding 
list of pathologic states regulated by intestinal microbi-
ota. We expect that there will be an explosion of activities 
in this area in the next few years. The next therapeutic 
approach for SCD patients might well be via manipula-
tion of the intestinal microbiota. For sickle cell VOC, the 
answer may lie in the intestine!
Abbrevations
SCD: sickle cell disease; VOC: vaso-occlusive crisis.
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